Calidi Biotherapeutics, Inc.
CLDI
$1.50
$0.000.00%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.90% | -14.62% | -21.70% | 18.94% | 12.36% |
| Total Depreciation and Amortization | 4.91% | 3.30% | 0.25% | 0.77% | 3.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -55.56% | -43.75% |
| Total Other Non-Cash Items | 20.61% | -0.20% | -5.88% | 77.44% | -54.73% |
| Change in Net Operating Assets | -68.66% | 97.79% | -34.89% | -282.65% | 24.32% |
| Cash from Operations | 13.16% | 31.57% | -31.50% | -9.64% | 9.97% |
| Capital Expenditure | 52.63% | -714.29% | -40.00% | 16.67% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 52.63% | -714.29% | -40.00% | 16.67% | -- |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -3.06% | 76.48% | -8,673.68% | -5.56% | 99.01% |
| Issuance of Common Stock | 202,966.67% | -99.97% | -26.06% | 264.85% | -32.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4,840.00% | 73.42% | 40.04% | -129.03% | 14.20% |
| Cash from Financing | 2,121.32% | -105.78% | -38.14% | 116.77% | 16.27% |
| Foreign Exchange rate Adjustments | -100.00% | -- | -- | 148.48% | -153.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 196.57% | -656.70% | -87.39% | 625.16% | 445.60% |